Karima Benameur

Karima Benameur

Auto-generated profile, based on publicly available information

Karima Benameur

Atlanta, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Emerging Infectious Diseases
Verified
Journal Article
Closed access
KBKarima Benameur
Karima Benameur
AAAnkita Agarwal
Ankita Agarwal
SASara C. Auld
Sara C. Auld
MBMatthew P. Butters
Matthew P. Butters
AWAndrew S. Webster
Andrew S. Webster
WHWilliam T. Hu
William T. Hu
Few detailed investigations of neurologic complications in severe acute respiratory syndrome coronavirus 2 infection have been conducted. We describe 3 patients with laboratory-confirmed coronavirus disease who showed development of encephalopathy and encephalitis. Neuroimaging showed nonenhancing unilateral, bilateral, and midline changes not readily attributable to vascular causes. All 3 patients had increased cerebrospinal fluid (CSF) levels of anti-S1 IgM. One patient who died also had increased levels of anti–envelope protein IgM. CSF analysis also showed markedly increased levels of interleukin (IL) 6, IL-8, and IL-10, but severe acute respiratory syndrome coronavirus 2 was not identified in any CSF sample. These changes provide evidence of CSF periinfectious/postinfectious inflammatory changes during coronavirus disease with neurologic complications.

18 September 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DJDinesh Jillella
Dinesh Jillella
NJNicholas J. Janocko
Nicholas J. Janocko
FNFadi Nahab
Fadi Nahab
KBKarima Benameur
Karima Benameur
JGJames G. Greene
James G. Greene
SRSrikant Rangaraju
Srikant Rangaraju
In the setting of the Coronavirus Disease 2019 (COVID-19) global pandemic caused by SARS-CoV-2, a potential association of this disease with stroke has been suggested. We aimed to describe the characteristics of patients who were admitted with COVID-19 and had an acute ischemic stroke (AIS). This is a case series of PCR-confirmed COVID-19 patients with ischemic stroke admitted to an academic health system in metropolitan Atlanta, Georgia (USA) between March 24th, 2020 and July 17th, 2020. Demographic, clinical, and radiographic characteristics were described. Of 396 ischemic stroke patients admitted during this study period, 13 (2.5%) were also diagnosed with COVID-19. The mean age of patients was 61.6 ± 10.8 years, 10 (76.9%) male, 8 (61.5%) were Black Americans, mean time from last normal was 4.97 ± 5.1 days, and only one received acute reperfusion therapy. All 13 patients had at least one stroke-associated co-morbidity. The predominant pattern of ischemic stroke was embolic with 4 explained by atrial fibrillation. COVID-19 patients had a significantly higher rate of cryptogenic stroke than non-COVID-19 patients during the study period (69% vs 17%, p = 0.0001). In our case series, ischemic stroke affected COVID-19 patients with traditional stroke risk factors at an age typically seen in non-COVID populations, and mainly affecting males and Black Americans. We observed a predominantly embolic pattern of stroke with a higher than expected rate of cryptogenic strokes, a prolonged median time to presentation and symptom recognition limiting the use of acute reperfusion treatments. These results highlight the need for increased community awareness, early identification, and management of AIS in COVID-19 patients.

4 August 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
ASAkanksha Sharma
Akanksha Sharma
CMChristina R. Maxwell
Christina R. Maxwell
JFJill Farmer
Jill Farmer
DGDiana Greene-Chandos
Diana Greene-Chandos
KLKathrin LaFaver
Kathrin LaFaver
KBKarima Benameur
Karima Benameur
Objective To test the hypothesis that US neurologists were experiencing significant challenges with lack of personal protective equipment (PPE), rapid changes in practice, and varying institutional protocols, we conducted this survey study. The current coronavirus disease of 2019 (COVID-19) pandemic has caused widespread disease and death. Rapid increases in patient volumes have exposed weaknesses in health care systems and challenged our ability to provide optimal patient care and adequate safety measures to health care workers (HCWs). Methods A 36-item survey was distributed to neurologists around the United States through various media platforms. Results Over a 1-week period, 567 responses were received. Of these, 56% practiced in academia. A total of 87% had access to PPE, with 45% being asked to reuse PPE due to shortages. The pandemic caused rapid changes in practice, most notably a shift toward providing care by teleneurology, although a third experienced challenges in transitioning to this model. Wide variations were noted both in testing and in the guidance provided for the exposed, sick, or vulnerable HCWs. Notably, 59% of respondents felt that their practices were doing what they could, although 56% did not feel safe taking care of patients. Conclusions Results from our survey demonstrate significant variability in preparedness and responsiveness to the COVID-19 pandemic in neurology, affected by region, health care setting, and practice model. Practice guidelines from professional societies and other national entities are needed to improve protection for physicians and their patients, promote recommended practice changes during a pandemic, and optimize future preparedness for public health emergencies.

5 October 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
DGDouglas J. Gelb
Douglas J. Gelb
JKJeff Kraakevik
Jeff Kraakevik
JSJoseph E. Safdieh
Joseph E. Safdieh
SASachin Agarwal
Sachin Agarwal
YOYazmin Odia
Yazmin Odia
RWRujuta Bhatt Wilson
Rujuta Bhatt Wilson
Medical students need to understand core neuroscience principles as a foundation for their required clinical experiences in neurology. In fact, they need a solid neuroscience foundation for their clinical experiences in all other medical disciplines also, because the nervous system plays such a critical role in the function of every organ system. Due to the rapid pace of neuroscience discoveries, it is unrealistic to expect students to master the entire field. It is also unnecessary, as students can expect to have ready access to electronic reference sources no matter where they practice. In the pre-clerkship phase of medical school, the focus should be on providing students with the foundational knowledge to use those resources effectively and interpret them correctly. This article describes an organizational framework for teaching the essential neuroscience background needed by all physicians. This is particularly germane at a time when many medical schools are re-assessing traditional practices and instituting curricular changes such as competency-based approaches, earlier clinical immersion, and increased emphasis on active learning. This article reviews factors that should be considered when developing the pre-clerkship neuroscience curriculum, including goals and objectives for the curriculum, the general topics to include, teaching and assessment methodology, who should direct the course, and the areas of expertise of faculty who might be enlisted as teachers or content experts. These guidelines were developed by a work group of experienced educators appointed by the Undergraduate Education Subcommittee (UES) of the American Academy of Neurology (AAN). They were then successively reviewed, edited, and approved by the entire UES, the AAN Education Committee, and the AAN Board of Directors.

14 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
TOTugba Ozturk
Tugba Ozturk
CHChristina Howell
Christina Howell
KBKarima Benameur
Karima Benameur
RRRichard P Ramonell
Richard P Ramonell
KCKevin S. Cashman
Kevin S. Cashman
WHWilliam T Hu
William T Hu
Background Accurate serological assays can improve the early diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but few studies have compared performance characteristics between assays in symptomatic and recovered patients. Methods We recruited 32 patients who had 2019 coronavirus disease (COVID-19; 18 hospitalized and actively symptomatic, 14 recovered mild cases), and measured levels of IgM (against the full-length S1 or the highly homologous SARS-CoV E protein) and IgG (against S1 receptor binding domain [RBD]). We performed the same analysis in 103 pre-2020 healthy adult control (HC) participants and 13 participants who had negative molecular testing for SARS-CoV-2. Results Anti-S1-RBD IgG levels were very elevated within days of symptom onset for hospitalized patients (median 2.04 optical density [OD], vs. 0.12 in HC). People who recovered from milder COVID-19 only reached similar IgG levels 28 days after symptom onset. IgM levels were elevated early in both groups (median 1.91 and 2.12 vs. 1.14 OD in HC for anti-S1 IgM, 2.23 and 2.26 vs 1.52 in HC for anti-E IgM), with downward trends in hospitalized cases having longer disease duration. The combination of the two IgM levels showed similar sensitivity for COVID-19 as IgG but greater specificity, and identified 4/10 people (vs. 3/10 by IgG) with prior symptoms and negative molecular testing to have had COVID-19. Conclusions Disease severity and timing both influence levels of IgM and IgG against SARS-CoV-2, with IgG better for early detection of severe cases but IgM more suited for early detection of milder cases.

26 November 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
NGNikhila Gandrakota
Nikhila Gandrakota
VPVishal B Patel
Vishal B Patel
MMMiranda A. Moore
Miranda A. Moore
KBKarima Benameur
Karima Benameur
MSMegha K Shah
Megha K Shah